Inhibikase Therapeutics (IKT) Equity Ratio (2020 - 2025)
Historic Equity Ratio for Inhibikase Therapeutics (IKT) over the last 6 years, with Q3 2025 value amounting to 0.92.
- Inhibikase Therapeutics' Equity Ratio rose 85550.68% to 0.92 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.92, marking a year-over-year increase of 85550.68%. This contributed to the annual value of 0.96 for FY2024, which is 2714.01% up from last year.
- According to the latest figures from Q3 2025, Inhibikase Therapeutics' Equity Ratio is 0.92, which was up 85550.68% from 0.9 recorded in Q2 2025.
- Inhibikase Therapeutics' Equity Ratio's 5-year high stood at 0.96 during Q4 2024, with a 5-year trough of 0.12 in Q3 2024.
- Moreover, its 5-year median value for Equity Ratio was 0.88 (2022), whereas its average is 0.79.
- Per our database at Business Quant, Inhibikase Therapeutics' Equity Ratio tumbled by 11443.35% in 2024 and then surged by 85550.68% in 2025.
- Quarter analysis of 5 years shows Inhibikase Therapeutics' Equity Ratio stood at 0.9 in 2021, then fell by 6.74% to 0.84 in 2022, then fell by 10.29% to 0.76 in 2023, then rose by 27.14% to 0.96 in 2024, then decreased by 4.81% to 0.92 in 2025.
- Its last three reported values are 0.92 in Q3 2025, 0.9 for Q2 2025, and 0.91 during Q1 2025.